Article Text

Download PDFPDF

  1. R. Conway1,2,
  2. E. Nikiphorou3,4,
  3. C. Demetriou5,
  4. C. Low6,
  5. K. Leamy7,
  6. J. Ryan8,
  7. R. Kavanagh9,
  8. A. Fraser10,11,
  9. J. Carey12,13,
  10. P. O’connell14,
  11. R. Flood15,
  12. R. Mullan2,15,
  13. D. Kane2,15,
  14. P. Robinson16,
  15. J. Liew17,
  16. R. Grainger18,
  17. G. Mccarthy7
  18. on behalf of COVID-19 Global Rheumatology Alliance
  1. 1St. James’s Hospital, Rheumatology, Dublin, Ireland
  2. 2Trinity College Dublin, Medicine, Dublin, Ireland
  3. 3King’s College Hospital, Rheumatology, London, Ireland
  4. 4King’s College London, Centre for Rheumatic Diseases, London, United Kingdom
  5. 5University of Nicosia Medical School, Primary Care and Population Health, Nicosia, Cyprus
  6. 6St. Vincent’s University Hospital, Rheumatology, Dublin, Ireland
  7. 7Mater Misericordiae University Hospital, Rheumatology, Dublin, Ireland
  8. 8Cork University Hospital, Rheumatology, Cork, Ireland
  9. 9Galway Clinic, Rheumatology, Doughiska, Ireland
  10. 10University Hospitals Limerick, Rheumatology, Limerick, Ireland
  11. 11University of Limerick, Graduate Entry Medical School, Limerick, Ireland
  12. 12Galway University Hospitals, Rheumatology, Galway, Ireland
  13. 13National University of Ireland Galway, Medicine, Galway, Ireland
  14. 14Beaumont Hospital, Rheumatology, Dublin, Ireland
  15. 15Tallaght University Hospital, Rheumatology, Dublin, Ireland
  16. 16University of Queensland, Medicine, Brisbane, Australia
  17. 17Boston University School of Medicine, Rheumatology, Boston, United States of America
  18. 18University of Otago, Medicine, Wellington, New Zealand


Background: There is limited data regarding the risk of hospitalisation in patients with rheumatic disease and COVID-19 in Ireland.

Objectives: We used the COVID-19 Global Rheumatology Alliance (GRA) registry data to study outcomes and their predictors.

Methods: We examined data on patients and their disease-related characteristics entered into the COVID-19 GRA provider registry from Ireland (24th March 2020 to 31st August 2020). Multivariable logistic regression was used to assess the association of demographic and clinical characteristics with hospitalisation.

Results: Of 105 patients, 47 (45.6%) were hospitalised and 10 (9.5%) died. Multivariable logistic regression analysis showed age (OR=1.06, 95%CI 1.01 to 1.10), number of comorbidities (OR=1.93, 95%CI 1.11 to 3.35), and glucocorticoid use (OR=15.01, 95%CI 1.77 to 127.16) were significantly associated with hospitalisation. A diagnosis of inflammatory arthritis was associated with a lower odds of hospitalisation (OR=0.09, 95%CI 0.02 to 0.32).

Conclusion: Increasing age, comorbidity burden, and glucocorticoid use were associated with hospitalisation, while a diagnosis of inflammatory arthritis was associated with lower odds of hospitalization.

Disclosure of Interests: Richard Conway Speakers bureau: Janssen, Roche, Sanofi, Abbvie, Elena Nikiphorou Speakers bureau: AbbVie, Eli-Lilly, Gilead, Celltrion, Pfizer, Sanofi, Christiana Demetriou: None declared, Candice Low: None declared, Kelly Leamy: None declared, John Ryan: None declared, Ronan Kavanagh: None declared, Alexander Fraser: None declared, John Carey: None declared, Paul O’Connell: None declared, Rachael Flood: None declared, Ronan Mullan: None declared, David Kane: None declared, Philip Robinson Speakers bureau: UCB, Roche, Pfizer, Gilead, Janssen, Novartis, Eli Lilly, Abbvie, Grant/research support from: Abbvie, UCB, Novartis, Janssen, Pfizer, Jean Liew Grant/research support from: Pfizer, Rebecca Grainger Speakers bureau: Pfizer, Cornerstones, Janssen, Novartis, Abbvie, Geraldine McCarthy: None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.